how are companies still selling compounded semaglutide 🏥 Dozens of compounding facilities distributing and and tirzepatide, even with the drugs no longer on the @US_FDA shortage list. A study in @JAMAHealthForum takes a deep Hims is in the crosshairs.

Inflammatory bowel disease presentation and diagnosis

Gland Pharma aims for mid-teen EBITDA margins for Cenexi in FY27, as the reorganisation on expanded capacity materialises

GLP-1 medications, by contrast, may face supply shortages, require specialty pharmacy fulfillment, and involve navigating prior authorization processes that can delay treatment by weeks

Collectively, NAD + exerts its effects not through traditional receptor binding but through its indispensable role as a co-substrate and regulator of these enzymatic systems, which sense and respond to fluctuations in NAD + levels to coordinate cellular metabolism, survival, DNA repair, signaling, and cell fate decisions 1-4